TPWA
LAB icon

TRUE Private Wealth Advisors’s Standard BioTools LAB Stock Holding History

TRUE Private Wealth Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$59K – 1103
2018
Q2 		$59K Hold
10,000
– – 0.01% 268
2018
Q1 		$58K Buy
+10,000
New +$65.7K 0.01% 224

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

TRUE Private Wealth Advisors's LAB Position: Q3 2018 in Review

TRUE Private Wealth Advisors sold out of Standard BioTools (LAB) in Q3 2018, closing a stake of 10,000 shares — an estimated $59K sold.

TRUE Private Wealth Advisors first reported a position in LAB in Q1 2018 and held it in 2 quarters. The position peaked at $59K in Q2 2018. 79 funds tracked by Wall St. Rank hold LAB as of Q3 2018.

  • TRUE Private Wealth Advisors reported no remaining Standard BioTools position as of Q3 2018 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 10,000 Standard BioTools shares in Q3 2018, an estimated $59K.
  • TRUE Private Wealth Advisors first reported a position in Standard BioTools in Q1 2018 and held it in 2 quarters.
  • TRUE Private Wealth Advisors's Standard BioTools position peaked at $59K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2018.

Based on TRUE Private Wealth Advisors's 13F filing for Q3 2018, filed 18 Oct 2018.